Related Experiment Video

Updated: Sep 4, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Treating non-small cell lung cancer by targeting the PI3K signaling pathway

Lin Jiang1,2, Jingbo Zhang2, Yan Xu1

  • 1Department of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.

Chinese Medical Journal
|July 13, 2022
PubMed

Insights

The phosphatidylinositol-3-kinase (PI3K) pathway is crucial in non-small cell lung cancer (NSCLC). PI3K inhibitors show promise for improving NSCLC treatment and patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Signal Transduction

Background:

  • The phosphatidylinositol-3-kinase (PI3K) signaling pathway regulates critical cellular functions including apoptosis, metabolism, and angiogenesis.
  • Lung cancer, particularly non-small cell lung cancer (NSCLC), has high mortality rates globally.
  • Conventional treatments for NSCLC offer limited survival benefits, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

  • To elucidate the role of the PI3K signaling pathway in the development and progression of NSCLC.
  • To review the current clinical research on PI3K pathway inhibitors in NSCLC treatment.
  • To discuss potential future development strategies for targeting the PI3K pathway in NSCLC.

Main Methods:

  • Literature review of studies investigating the PI3K pathway in NSCLC.
  • Analysis of clinical trial data for PI3K inhibitors in NSCLC.
  • Synthesis of current research findings and future directions.

Main Results:

  • The PI3K pathway is implicated in the pathogenesis of NSCLC.
  • Numerous PI3K pathway inhibitors are under investigation in clinical trials for NSCLC.
  • Targeting the PI3K pathway represents a promising avenue for molecular therapy in NSCLC.

Conclusions:

  • The PI3K signaling pathway is a key player in NSCLC.
  • Targeted therapies inhibiting the PI3K pathway are advancing clinical research for NSCLC.
  • Further development of PI3K inhibitors may significantly improve NSCLC patient survival and prognosis.

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.3K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.7K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
248
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.2K